Acurastem Receives CIRM Grant for Targeted Therapeutic Program for ALS/FTD | AFTD
AcuraStem received a $4 million grant from CIRM to advance its UNC13A program targeting ALS and FTD, using the iNeuroRx platform to develop antisense oligonucleotides that restore normal function disrupted by TDP-43 pathology.
Reference News
Acurastem Receives CIRM Grant for Targeted Therapeutic Program for ALS/FTD | AFTD
AcuraStem received a $4 million grant from CIRM to advance its UNC13A program targeting ALS and FTD, using the iNeuroRx platform to develop antisense oligonucleotides that restore normal function disrupted by TDP-43 pathology.